Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis Reports First Quarter 2018 Financial Results

Total revenues increased by 25%, driven by SPINRAZA royalties More than $2 billion of cash expected upon closing of Biogen transaction Expanded strategic neurology research collaboration with Biogen and invested in TEGSEDI™ commercialization through Akcea Conference call and webcast today, May 4,